Drug Trial Radar · NCT05348122
A Study of TG103 Injection in Type 2 Diabetes Subjects
Last checked: Nov 19, 2026Latest source record: Jun 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
240
Planned (sponsor's estimate)
Start
Jun 15, 2022
Primary completion
Nov 1, 2023
Study completion Nov 1, 2023
Sponsor
- Lead sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this trial is to evaluate the efficacy of different doses and frequencies of administration of TG103 injection in the treatment of type 2 diabetes.
Conditions
- Type 2 Diabetes Mellitus
Interventions
TG103,Q2WDrug
TG103 injection will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
TG103,QWDrug
TG103 injection will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
Placebo,Q2WDrug
Placebo will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
Placebo,QWDrug
Placebo will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
Dulaglutide,QWDrug
Dulaglutide will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in glycosylated hemoglobin (HbA1c) from baseline to week 17Time frame: Baseline through Day 113
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Gao Huanhuan
Shijiazhuang, Hebei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.